Post the presentation at the 2025 JPMorgan Healthcare Conference by Sarepta (SRPT), JPMorgan notes the Elevidys launch remains strong with a solid beat, accompanied by a beat on PMO revenues as well. 2025 net product guidance was unchanged, the firm adds. JPMorgan also says that as expected, the company did not have data related the Arrowhead collaboration (ARWR), however, the company did provide some timeline updates. The firm has an Overweight rating on Sarepta.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta reports preliminary Q4 net product revenue $638.2M
- Sarepta price target lowered to $165 from $182 at RBC Capital
- 5 “Strong Buy” Healthcare Stocks to Buy Before They Soar in 2025
- Sarepta wins first phase of Nippon Shinyaku gene-therapy trial
- Sarepta completes enrollment in the EMERGENE study of SRP-9003